Shuxian An

746 total citations
26 papers, 538 citations indexed

About

Shuxian An is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Shuxian An has authored 26 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Molecular Biology. Recurrent topics in Shuxian An's work include Peptidase Inhibition and Analysis (7 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Shuxian An is often cited by papers focused on Peptidase Inhibition and Analysis (7 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Shuxian An collaborates with scholars based in China, Chile and Italy. Shuxian An's co-authors include Gang Huang, Liang Shi, Weijun Wei, You Zhang, Mengqin Shen, Li Zhao, Jianjun Liu, Jianjun Liu, Di Zhang and Hui Yan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Molecular Cancer and Journal of Nuclear Medicine.

In The Last Decade

Shuxian An

25 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuxian An China 14 266 160 149 114 61 26 538
Matthias Sommer United States 10 416 1.6× 101 0.6× 223 1.5× 115 1.0× 55 0.9× 14 639
Wenyan Wang China 16 232 0.9× 59 0.4× 90 0.6× 177 1.6× 41 0.7× 44 541
Felix Meyer Germany 10 341 1.3× 46 0.3× 289 1.9× 159 1.4× 117 1.9× 20 646
Cory Mavis United States 16 441 1.7× 66 0.4× 285 1.9× 77 0.7× 29 0.5× 74 754
Xinhong He China 13 224 0.8× 70 0.4× 125 0.8× 165 1.4× 83 1.4× 30 484
Gilberto S. Almeida United Kingdom 10 153 0.6× 51 0.3× 86 0.6× 114 1.0× 67 1.1× 16 336
Changwen Jing China 15 301 1.1× 31 0.2× 154 1.0× 275 2.4× 143 2.3× 32 582
Chang‐Ying Guo China 10 527 2.0× 43 0.3× 155 1.0× 396 3.5× 79 1.3× 23 769
Imke Beier Germany 8 165 0.6× 89 0.6× 112 0.8× 51 0.4× 22 0.4× 12 371

Countries citing papers authored by Shuxian An

Since Specialization
Citations

This map shows the geographic impact of Shuxian An's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuxian An with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuxian An more than expected).

Fields of papers citing papers by Shuxian An

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuxian An. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuxian An. The network helps show where Shuxian An may publish in the future.

Co-authorship network of co-authors of Shuxian An

This figure shows the co-authorship network connecting the top 25 collaborators of Shuxian An. A scholar is included among the top collaborators of Shuxian An based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuxian An. Shuxian An is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, You, et al.. (2025). CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study. Journal of Nuclear Medicine. 66(6). 865–872. 1 indexed citations
2.
Li, Lianghua, You Zhang, Shuxian An, et al.. (2025). CD70-Targeted [ 18 F]RCCB6 Immuno-PET/CT for Diagnosing Clear Cell Renal Cell Carcinoma Metastases: A Prospective Study. Journal of Nuclear Medicine. 67(3). 397–403. 1 indexed citations
3.
An, Shuxian, Lu Wang, Fang Xie, et al.. (2024). Pathway to Approval of Innovative Radiopharmaceuticals in China. Journal of Nuclear Medicine. 65(Supplement 1). 72S–76S. 3 indexed citations
4.
Zhang, You, Wei Huang, Shuxian An, et al.. (2024). ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study. European Journal of Nuclear Medicine and Molecular Imaging. 52(2). 388–400. 4 indexed citations
5.
Shen, Mengqin, et al.. (2024). PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability. Cellular Signalling. 119. 111184–111184. 5 indexed citations
6.
Huang, Wei, Min Cao, You Zhang, et al.. (2024). Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation. Journal of Nuclear Medicine. 65(12). jnumed.124.268751–jnumed.124.268751. 2 indexed citations
7.
Huang, Wei, Gang Huang, Shuxian An, & Jianjun Liu. (2023). Molecular imaging of pancreatic ductal adenocarcinoma. SHILAP Revista de lepidopterología. 4(5). 3 indexed citations
8.
An, Shuxian, et al.. (2023). The added diagnostic value of 18F-FDG PET/CT radiomic analysis in multiple myeloma patients with negative visual analysis. Nuclear Medicine Communications. 45(3). 244–252. 1 indexed citations
9.
Huang, Wei, Chenyi Liang, You Zhang, et al.. (2023). ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. European Journal of Nuclear Medicine and Molecular Imaging. 51(2). 380–394. 21 indexed citations
10.
Huang, Wei, Yizhen Pang, Qiufang Liu, et al.. (2023). Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study. Research. 6. 282–282. 14 indexed citations
11.
Wei, Weijun, Di Zhang, You Zhang, et al.. (2022). Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2. Molecular Therapy — Oncolytics. 27. 305–314. 19 indexed citations
12.
An, Shuxian, Di Zhang, You Zhang, et al.. (2022). GPC3-targeted immunoPET imaging of hepatocellular carcinomas. European Journal of Nuclear Medicine and Molecular Imaging. 49(8). 2682–2692. 60 indexed citations
13.
Wang, Cheng, Yumei Chen, Yun Nan Hou, et al.. (2021). ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. European Journal of Nuclear Medicine and Molecular Imaging. 48(9). 2749–2760. 47 indexed citations
14.
Li, Jiajin, Yumei Chen, Shuxian An, et al.. (2021). PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer. International Journal of Medical Sciences. 18(14). 3150–3157. 4 indexed citations
15.
Wei, Weijun, Di Zhang, You Zhang, et al.. (2021). Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053. Molecular Pharmaceutics. 19(10). 3502–3510. 16 indexed citations
16.
Shi, Liang, Shuxian An, Ying Liu, Jianjun Liu, & Feng Wang. (2020). <p>PCK1 Regulates Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma Through LDHA</p>. OncoTargets and Therapy. Volume 13. 2613–2627. 30 indexed citations
17.
An, Shuxian, Liangqian Huang, Ping Miao, et al.. (2018). Small ubiquitin-like modifier 1 modification of pyruvate kinase M2 promotes aerobic glycolysis and cell proliferation in A549 human lung cancer cells. OncoTargets and Therapy. Volume 11. 2097–2109. 24 indexed citations
18.
Shen, Mengqin, Xiaoping Zhao, Li Zhao, et al.. (2018). Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer. Molecular Cancer. 17(1). 88–88. 37 indexed citations
19.
Li, Ting, Jun Liu, Shuxian An, Yan Dai, & Qing Yu. (2014). Body mass index and mortality in patients on maintenance hemodialysis: a meta-analysis. International Urology and Nephrology. 46(3). 623–631. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias Sommer Breakdown of academic impact, for papers by Wenyan Wang Breakdown of academic impact, for papers by Felix Meyer Breakdown of academic impact, for papers by Cory Mavis Breakdown of academic impact, for papers by Xinhong He Breakdown of academic impact, for papers by Gilberto S. Almeida Breakdown of academic impact, for papers by Changwen Jing Breakdown of academic impact, for papers by Chang‐Ying Guo Breakdown of academic impact, for papers by Imke Beier
Rankless by CCL
2026